A non-diabetic patient with favorable genetic predispositions in these pathways may experience more robust weight loss, while others with less favorable variants may require higher doses or longer timelines to see meaningful results
Classic examples include native GLP-1, which has a plasma half-life of approximately 2 minutes and required continuous infusion in early studiesan impractical route for chronic therapyyet was subsequently transformed into a once-weekly therapeutic through lipidation and albumin-binding strategies ( Third, pleiotropic signaling that aligns with physiological function rather than nonspecific toxicity favors re-evaluation
It is chemically 97% similar to this hormone, making it extremely effective
Glucagon-like peptide-1 (GLP-1) receptor agonistsincluding semaglutide (Ozempic, Wegovy), dulaglutide (Trulicity), and liraglutide (Victoza, Saxenda)along with tirzepatide (Mounjaro, Zepbound), a dual GIP/GLP-1 receptor agonist, have transformed the management of type 2 diabetes and obesity